Product covers key cancer treatment costs, including targeted anticancer drug therapy

Monthly premium starts in the 20,000 won range for a 40-year-old male

[DB Insurance]
[DB Insurance]

DB Insurance announced Monday the launch of an online-only mini cancer insurance product, "Cham Joeun Cancer Insurance (Mini Cancer Plan)," designed to cover major cancer treatment costs.

The product is DB Insurance's first online-exclusive mini cancer insurance offering. It is built around core coverage for cancer treatment, including major cancer treatment costs, major treatment costs for other skin cancers and thyroid cancer, ongoing anticancer radiation and drug therapy, and ongoing targeted anticancer drug licensed treatment.

Most existing cancer insurance products have been structured primarily around one-time diagnosis benefit payouts, leaving policyholders ill-equipped to handle high ongoing treatment costs. The new product allows existing cancer insurance holders to purchase it as supplemental coverage to fill those gaps.

For a 40-year-old male enrolling with coverage of 1 million won for cancer diagnosis (excluding borderline cancers), 200,000 won for borderline cancer diagnosis, 20 million won for major cancer treatment, 4 million won for major treatment of other skin cancers and thyroid cancer, 1 million won for ongoing anticancer radiation and drug therapy, and 50 million won for ongoing targeted anticancer drug licensed treatment, the monthly premium falls in the 20,000 won range.

DB Insurance said it moved to strengthen treatment cost coverage because advances in medical technology have raised cancer survival rates while also extending treatment periods, increasing the financial burden on patients.

According to the Ministry of Health and Welfare's National Cancer Registry Statistics (2023) and the National Health Insurance Service's survey on medical expenses for national health insurance patients (2024), the five-year relative survival rate for cancer patients rose from 54.2 percent in 2001–2005 to 73.7 percent in 2019–2023, meaning more than seven in 10 cancer patients now survive beyond five years. However, the financial burden of treatment remains significant as non-covered procedures increase. National health insurance covers 75 percent of cancer-related costs, leaving patients responsible for the remaining 25 percent.

"The rise in cancer survival rates is a positive outcome of earlier detection and advances in new medical technologies such as targeted and immunotherapy anticancer drugs, but prolonged cancer treatment translates into serious financial risk for patients," a DB Insurance official said. "We will continue to work actively to develop better cancer insurance products so our customers can focus solely on their treatment without financial worry."


won@heraldcorp.com